4D Molecular Therapeutics News

4DMT Announces Presentations at ARVO 2024 Annual Meeting

Preclinical data for 4D-175 for geographic atrophy to be presented in an oral presentation4D-150 PRISM randomized Phase 2 Dose Expansion Cohort (N=51) 24-week encore results to be presented in a poster EMERYVILLE,

GlobeNewswireMay 1 08:00 ET

4D Molecular Therapeutics(FDMT.US) Officer Sells US$45,045 in Common Stock

$4D Molecular Therapeutics(FDMT.US)$ Officer Bizily Scott sold 1,750 shares of common stock on Apr 16, 2024 at an average price of $25.74 for a total value of $45,045.Source: Announcement What is stat

moomoo NewsApr 18 21:31 ET

4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital

4D Molecular Therapeutics Is Maintained at Outperform by RBC Capital

Dow JonesApr 15 13:23 ET

RBC Capital Maintains Outperform on 4D Molecular Therapeutics, Raises Price Target to $40

RBC Capital analyst Luca Issi maintains 4D Molecular Therapeutics (NASDAQ:FDMT) with a Outperform and raises the price target from $35 to $40.

BenzingaApr 15 13:13 ET

4D Molecular Therapeutics New Overweight at Barclays on Genetic Medicine Platform

Seeking AlphaApr 15 12:22 ET

RBC Capital Reaffirms Their Buy Rating on 4D Molecular Therapeutics (FDMT)

TipRanksApr 15 06:55 ET

Express News | 4D Molecular Therapeutics Inc : Barclays Initiates Coverage With Overweight Rating and Target Price $45

Moomoo 24/7Apr 15 06:31 ET

Express News | 4D Molecular Therapeutics Inc : RBC Raises Target Price to $40 From $35

Moomoo 24/7Apr 15 05:13 ET

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Acadia Healthcare (ACHC) and Coherus Biosciences (CHRS)

TipRanksApr 15 04:30 ET

4D Molecular Therapeutics Insider Sold Shares Worth $259,102, According to a Recent SEC Filing

Scott Bizily, Chief Legal Officer, on April 01, 2024, sold 8,153 shares in 4D Molecular Therapeutics (FDMT) for $259,102. Following the Form 4 filing with the SEC, Bizily has control over a total of 1

MT NewswiresApr 4 10:39 ET

4D Molecular Therapeutics Inc (FDMT) Chief Legal Officer Scott Bizily Sells 8,153 Shares

Yahoo FinanceApr 4 01:30 ET

4D Molecular Therapeutics(FDMT.US) Officer Sells US$259.1K in Common Stock

$4D Molecular Therapeutics(FDMT.US)$ Officer Bizily Scott sold 8,153 shares of Common Stock on Apr 1, 2024 at an average price of $31.78 for a total value of $259.1K.Source: Announcement What is state

moomoo NewsApr 3 20:02 ET

4D Molecular Therapeutics Price Target Cut to $63.00/Share From $70.00 by BMO Capital

4D Molecular Therapeutics Price Target Cut to $63.00/Share From $70.00 by BMO Capital

Dow JonesApr 1 12:28 ET

4D Molecular Therapeutics Is Maintained at Outperform by BMO Capital

4D Molecular Therapeutics Is Maintained at Outperform by BMO Capital

Dow JonesApr 1 12:28 ET

Express News | Jefferies Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $58

Moomoo 24/7Apr 1 10:49 ET

Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Biogen (BIIB)

TipRanksApr 1 08:10 ET

4D Molecular Therapeutics Inc's Chief Legal Officer Sells Company Shares

Yahoo FinanceMar 29 19:01 ET

4D Molecular Therapeutics(FDMT.US) Officer Sells US$204.41K in Common Stock

$4D Molecular Therapeutics(FDMT.US)$ Officer Bizily Scott sold 5,833 shares of Common Stock on Mar 27, 2024 at an average price of $35.0438 for a total value of $204.41K.Source: Announcement What is s

moomoo NewsMar 29 17:36 ET

Optimistic Outlook for 4D Molecular Therapeutics Ahead of Regulatory Update on CF Gene Therapy 4D-710

TipRanksMar 29 03:08 ET

4D Molecular Reports Regulatory Updates on 4D-710 For Cystic Fibrosis

4D Molecular Therapeutics (FDMT) said it conducted initial pivotal study interactions with the US Food and Drug Administration and European Medicines Agency over its development plans for 4D-710 for t

MT NewswiresMar 28 14:32 ET